New trial
Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Advanced Melanoma
- Trial ID
- NCT06961357 on ClinicalTrials.gov
- Cancer type
- Melanoma
- Published in
- New in Oncology - May 21, 2025
This trial is evaluating a single dose of CD40L-augmented TIL therapy in advanced melanoma patients—including those with rare subtypes—after failure of standard treatment, with lymphodepletion and a short course of IL-2 to assess safety and preliminary efficacy.
More in melanoma
-
New trial · Oct 22, 2026 · NCT07869381
Randomized trial compares comprehensive margin assessment with standard pathology after melanoma surgery -
New trial · Oct 15, 2026 · NCT07830225
Phase 2 pilot uses ctDNA to guide checkpoint-inhibitor discontinuation in advanced melanoma with disease control -
Trial result · Oct 8, 2026 · NCT06566092
Lifileucel produces confirmed responses in 2 of 3 treated adolescents with ICI-refractory metastatic melanoma -
New trial · Oct 8, 2026 · NCT07804186
Phase 3 darovasertib PKC inhibitor plus crizotinib c-MET/ALK inhibitor in adjuvant uveal melanoma -
New trial · Oct 8, 2026 · NCT07815574
Phase 3 iSCIB1+ gp100/TRP-2 DNA vaccine adds melanoma antigen targeting to PD-1/CTLA-4 blockade.